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EDITORIAL SUMMARY A protocol for producing exosomes loaded with ultrathin Palladium 
nanosheets for targeted bioorthogonal catalysis. Exosomes are isolated by ultracentrifugation and 
Pd precursors are loaded in their interior by diffusion and reduced into metallic nanosheets using 
gas phase CO. 
TWEET A new protocol for non-disruptive loading of Pd #nanosheets into #exosomes for 
targeted #bioorthogonal #catalysis. 
 
COVER TEASER Non-destructive production of Pd-loaded exosomes 
Please indicate up to four primary research articles where the protocol has been used 
and/or developed (including DOI). 
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The use of exosomes as selective delivery vehicles of therapeutic agents, such as drugs or hyperthermia-
capable nanoparticles is being intensely investigated on account of their preferential tropism towards their 
parental cells. However, the methods used to introduce a therapeutic load inside exosomes often involve 
disruption of their membrane, which may jeopardize their targeting capabilities, attributed to their surface 
integrins. On the other hand, in recent years bioorthogonal catalysis has emerged as a new tool with a 
myriad of potential applications in medicine. These bioorthogonal processes, often based on Pd-catalyzed 
chemistry, would benefit from systems capable of delivering the catalyst to target cells. It is therefore 
highly attractive to combine the targeting capabilities of exosomes and the bioorthogonal potential of Pd 
nanoparticles to create new therapeutic vectors. In this protocol, we provide detailed information on an 
efficient procedure to achieve a high load of catalytically active Pd nanosheets inside exosomes, without 
disrupting their membranes. The protocol involves a multistage process in which exosomes are first 
harvested, subjected to impregnation with a Pd salt precursor followed by a mild reduction process using 
gas phase CO which acts as both reducing and growth-directing agent to produce the desired nanosheets. 
The technology is scalable and the protocol can be conducted by any researcher having basic biology and 




Bioorthogonal chemistry provides exciting opportunities in medicine by allowing in situ synthesis of 
functional molecules that are useful as probes to provide information of ongoing biochemical processes 
and/or drugs capable of modulating physiological or pathological processes.1,2 As in other fields of 
chemistry, in a bio-orthogonal scenario the use of catalysis is effective to facilitate multiple cycles of 
selected chemical reactions and such approach is being widely explored for different applications, giving 
rise to the subfield of bioorthogonal catalysis3-6. In particular, Pd has often been used as the catalyst of 
choice, given its flexibility to enable a wide variety of reactions (e.g. dealkylations,7-14 cross-coupling 
reactions,7,14-17 ring formation18, cleavage19, etc.). The use of intra-tumor Pd-catalyzed chemistry to 
generate toxic species in situ from molecules having low toxicity (e.g. through catalyzed uncaging 
reactions) would be of enormous interest in oncology, as systemic administration of the drug would be 
replaced by a localized intra-tumoral production3-6, potentially reducing side effects by orders of 
magnitude.8,12 While proof of concept demonstrations have been achieved in vitro, ex vivo and in vivo,8,10-
13,20-22 the use of bioorthogonal catalytic chemistry in vivo faces enormous challenges. The main obstacle 
to be cleared refers to the fact that the catalyst (e.g. Pd nanoparticles) must be selectively delivered to the 
target cells or tissues within the organism. A similar problem has been faced for a long time by 
researchers working on selective drug delivery using nanoscale vectors, with tumors often being the target 
of the encapsulated drug22-27. In response to this challenge, a range of nanoparticle-based drug delivery 
systems (organic and inorganic, with a variety of stealth covers and targeting moieties) has been 
developed, although the delivery efficiency is poor: on average, less than one percent of the administered 
nanoparticle dose reaches the tumor, even for highly sophisticated antibody-grafted nanoparticles.28 
To address the challenge of delivering Pd catalysts specifically to cancer cells, our laboratories have 
recently reported the use of cancer-derived exosomes as targeted carrier systems.29 Exosome-based 
delivery is raising huge interest as a more effective alternative way to deliver catalysts to tumors.30-32 
Exosomes are nanoscale extracellular entities known since the early 1980s when they were defined as 
vesicles produced by exfoliation of cell membranes.33 They are secreted by most cells in the organism and 
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for a long time it was thought that their main function was to dispose unwanted material out of the cell. 
Today, it is known that exosomes contain a number of key components from the parental cell including 
proteins, lipids and nucleic acids, and play a crucial role in cell to cell communication.34,35 More 
importantly, there are strong indications that the exosomal membrane may confer unique identification 
properties to these vesicles that could allow selective targeting towards their cells of origin.32,36,37 We 
have developed a method that allows loading a wide variety of cell derived exosomes with Pd nanosheets. 
The synthesis procedure is based on the insitu reduction of Pd metal precursors previously encapsulated 
by diffusion within the exosomes. A mild chemical gas-phase methodology was developed to enable the 
controlled assembled of Pd nanosheets inside exosomes, without compromising their integrity and 
functionality. Our diffusion-based method for loading the Pd precursor into exosomes allows to solve the 
main problem when using exosomes as catalytic delivery vectors: to introduce the desired payload inside 
the exosomes without disrupting the exosomal membrane. Here we present a detailed protocol to create 
exosome-catalyst hybrids that preserves the inherent properties of exosomes and incorporates the 
bioorthogonal activity of the catalyst. 
Applications of the method 
... 
Comparison with other methods 
Conventional methods to introduce metallic nanoparticles inside exosomes include aggressive methods 
such as electroporation, sonication or thermal shock, and milder methods such as incubation24. We studied 
these procedures in a previous work24  and concluded that not only these methods showed a poor yield of 
nanoparticle-loaded exosomes, but also that especially the most severe methods produced significant 
damage to the exosomes, resulting in impaired morphology and damaged exosomal membranes. In 
addition, using those previous methods, the ability to control the amount of the catalytic cargo inside the 
exosomes is limited.  We and others obtained improved results by leveraging the physiological biogenesis 
pathway: in this case, the parental cells are incubated with the desired nanoparticles to allow endocytosis 
followed by excretion via the exosomal route.32,38 In this way the exosomes are naturally loaded with the 
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desired nanoparticles, allowing to preserve the key features of their membrane. However, this method 
faces important limitations to produce catalyst-loaded exosomes. First, the catalytic nanoparticle itself 
must be biocompatible: since the cell biological mechanisms are used to generate loaded exosomes, the 
cell must be alive and completely functional, and the load must be necessarily non-toxic at the doses used. 
Second, it is not possible to control the load of the catalyst inside the exosomes. The catalyst-loaded 
exosomes are formed in a complex process: nanoparticles are internalized by endocytosis and enclosed 
into multivesicular bodies that eventually fuse with the cellular membrane to produce exosomes.24,39 In 
contrast, our recently developed method29 works with exosomes that are harvested and purified from cell 
cultures, then incubated with the desired catalyst precursor and finally subjected to a mild reduction 
process to generate the active catalyst. The amount of catalyst inside the exosomes can be tuned by 
controlling the concentration of the precursor solution and/or the diffusion time. 
Limitations 
The procedure described here could be applied to the majority of the cells lines, but also to exosomes 
obtained from any other source, including fluids from the organism (serum, urine, saliva, etc.), explants or 
concentrates from different tissues. However, along with the critical steps highlighted in the procedure, 
there are possible limitations to be considered: 1) A multidisciplinary team is necessary to enable the 
proper culture of cells to isolate exosomes, and then treat them in a well-equipped chemical engineering 
lab facility to manipulate the toxic CO gas at high pressure. Cryo-Transmission Electron microscopy, 
Energy Dispersive X-ray Spectroscopy (EDS) analysis, Microwave Plasma Atomic Emission 
Spectroscopy (MP-AES) and an ultracentrifuge are also required to validate the quality of the resulting Pd 
modified exosomes for their biomedical use. 2) The exogenous production of exosomes relies on the 
understanding of exosome biogenesis pathway, since the exosome harvesting and isolation protocols 
could vary between cell lines from different sources. 3) The size of exosomes produced can be different 
for different cell lines, this fact may require optimization of the isolation conditions to avoid an inefficient 
separation. 4) The promising potential of bioorthogonal catalysis in biomedicine inspires new strategies to 
produce bioactive agents, regulating their activity in living systems. However, to achieve this, it is not 
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only crucial to nanoengineer biocompatible catalysts and produce customized inactive prodrugs, but also 
to choose the right vector to deliver abiotic catalysts into designated locations. Then, it is key not to 
modify the functionality of exosomes with any supporting reagent such as the ones usually considered in 
wet chemistry procedures, such as reducing agents and stabilizers. The use of those reagents could modify 
the chemical functionality of exosomes and their preferential tropism to progenitor cells, which would 
unable the bioactive agent production in targeted therapies.  
Experimental design 
The entire procedure includes the following stages: cell culture and exosome isolation (Steps 1-21), 
exosome concentration determination (Steps 22-23), loading of exosomes with Pd precursor by diffusion 
(Steps 24-28), setup of the high pressure CO reduction system and assembly of Pd nanosheets inside 
exosomes (Steps 29-51), Pd-exosome characterization (Steps 52-153) and Pd-exosome activity test with a 
fluorogenic sensor in vitro (Steps 167-178) and inside cancer cells (Steps 154-166) (Fig 1). The 
individual stages are discussed in detail in the following sections. 
Cell culture and exosome isolation. Differences in the protein, genetic and lipid contents and surface 
composition and their relative abundances, can be observed in exosomes secreted from different parental 
cells40. These components do not only determine effective targeting of the exosomes, but also they could 
potentially interfere with the diffusion of metal precursors.3 These considerations should be taken into 
account when adopting this method to other cell types. We have successfully tested our approach in four 
different cell lines: 1&2) mouse melanoma cell lines with two aggressive states, low metastatic B16-F1 
and high metastatic B16F10; 3) non-small cell lung carcinoma (NSCLC) A549 cells and 4) human 
placenta-derived mesenchymal stem cells (hPMSCs) (see Anticipated Results). Lung cancer is the most 
common cause of cancer-related death in men and second most common in women after breast cancer41. 
Approximately 80% of lung cancer is NSCLC4, which has prompted us to also test our approach on a 
widely used human NSCLC cell line, A5495 6 Based on the results with the 4 cell lines shown in the 
Anticipated Results section, we postulate that our approach can be used with a wider range of exosomes, 
including coming from many other cell lines and with exosomes isolated from blood and tissues. When 
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adapting the approach for different cell lines, it is important to consider cell growth rate to optimize the 
purification  and amounts of exosomes obtained. Researcher should take into account whether his/her cell 
line secretes high amounts of exosomes to calculate the starting cell amount to be seeded. For different 
and more complex exosome sources such as tissue, blood, urine, etc., additional purification steps might 
be employed such as sucrose gradient or an immunocapture procedure. 
Another determinant factor would be the lipidic membrane composition from each type of exosome. 
Their membrane might change amongst different sources and the resistance to the procedure (CO, toxicity 
of the materials etc.) might be crucial. It should be tested for each type of exosome.  
Exosome isolation is challenging because the purity and quality of the final exosomes depend on 
the presence of non-exosomal impurities (“contaminants”), which is strongly affected by the procedure 
considered for the removal of those impurities. Cells must therefore be tested regularly for mycoplasma 
contamination before use. Ultracentrifugation is the method used in this protocol (Steps 6-21), since this 
is the most widely used primary isolation method from conditioned cultured media. However, alternative 
approaches such as density gradient centrifugation, ultrafiltration, size-exclusion chromatography, charge 
neutralization-based precipitation, magnetic affinity purification, and the use of microfluidic devices 
based on different principles42-44 are also applicable to isolate exosomes from complex biological fluids.  
 
Exosome concentration determination. Following isolation, the exosome content is determined by 
measuring the total protein concentration (Steps 22-23). This is a key procedure to control the loading of 
Pd nanosheets inside the exosomes, as well as for their final application as bioorthogonal catalyst. 
 
Loading of exosomes with Pd precursor by diffusion. Our approach uses a passive cargo loading 
approach based on diffusion (Steps 24-28) to avoid damage to the exosome instead of alternative 
mechanically disruptive approaches (see Comparison with other methods). This approach relies on the 
passive diffusion of Pd2+ cations through the lipid membrane of exosomes according to the Fick´s law, 
where the Pd2+ concentration gradient is the driving force. Given the small size of the exosomes (short 
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diffusion length) and the high diffusivity of Pd2+ ions, the time required for their diffusion into exosomes 
is likely to be short, and therefore incubation time or temperature (which has a direct effect on diffusion 
coefficients) are not the main variables, since the incubation time used is already sufficient to achieve 
equilibration of Pd2+ concentration. Instead, the concentration of Pd2+ in the surrounding solution seems to 
be the main factor to determine the total Pd load in the exosomes that will be achieved upon CO 
reduction. Despite the differences in the exact composition of the lipidic membrane bilayer structure of 
the exosomes having the characteristic surface ligands and receptors from source cells; the diffusion-
driven approach here described for loading Pd precursors is very versatile and used in all different 
exosomes.   
 
Setup of the high-pressure carbon monoxide reduction system and assembly of Pd nanosheets 
inside exosomes. After loading the Pd2+ cations, Pd nanosheets are formed inside the exosomes by CO-
mediated reduction (Steps 38-51). We chose a soft reducing agent to minimize side reactions during 
exosome treatment, as most reductants that are capable of reducing Pd2+ species could potentially react 
with functional groups present in biomolecules composing the exosome. We have optimized the 
procedural conditions for each step of the protocol to promote Pd nanoparticle formation without causing 
functional defects in the exosomes. In addition, the high pressure of CO assures a high CO solubility in 
the reaction media, which is key to control the anisotropic shape of Pd nanosheets. This fact is explained 
because in addition to its reductant role, CO also acts as capping agent since it is selectively chemisorbed 
on different facets and at active sites of Pd nanocrystals.45,46 A mild temperature (30 ºC) is used to prevent 
exosome damage. Finally, CO is a gas which means that it can be easily removed after its use with the aid 
of inter gas pressure swing cycles. We designed a high-pressure system to manipulate CO, a toxic gas, 
which requires some basic safety measures to assure its appropriated management. 
 
Pd-exosome characterization. We describe a variety of characterization techniques to determine the 
functionality of the exosomes (Steps 52-104), Pd loading (Steps 105-110), their stability (Steps 111-114), 
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toxicity (Steps 115-124), cellular uptake and localization (Steps 125-150), morphology and structure 
(Steps 151-162). 
 
Pd-exosome activity test with a fluorogenic sensor in vitro and inside cells. The catalytic activity 
of the Pd exosomes is tested under physiological conditions (PBS, 37ºC) using the Palladium sensitive 
off-on sensor 7-propargyloxy-3H-phenoxazin-3-one (Pro-Res) (Steps 154-166).29 The small size and 
lipophilic properties of Pro-Res allows its passive diffusion across exosomal membranes. Once inside the 
exosome, nonfluorescent Pro-Res undergoes a single Pd-catalyzed dealkylation reaction to produce 
highly-fluorescent resorufin, which passively diffuses back into the medium. Thereby the reaction 
monitoring is facilitated by a simple fluorometric analysis of the reaction medium or by time-lapsed 
imaging. Pro-Res shows negligible fluorescence emission under white LED excitation, while resorufin 
exhibits >200-fold superior fluorescence intensity at Ex/Em 540 /590 nm.29 To validate the results, it is 
essential to perform the same test with unmodified exosomes as a negative catalytic control. 
Finally, to validate both the cell targeting and catalytic properties of the exosome-catalyst hybrid, 
exosomes are incubated with their cells of origin (e.g. A549) at different time-points (from 1 to 24 h) in 
order to determine the time of maximum internalization of the vector inside the cells. Next, the culture 
medium is removed and the cells are carefully washed with PBS to eliminate all non-internalized 
exosomes. Cells are then detached and incubated with a solution of Pro-Res in culture medium. The 
lipophilic properties of Pro-Res and resorufin facilitate back and forth diffusion of the reagents through 
the cell and exosome membranes, which allows monitoring the Pd-catalyzed synthesis of resorufin (and 
the reaction yield) by the fluorometric analysis of the medium (without cells). To validate the results, it is 
essential to perform the same test with unmodified exosomes as a negative catalytic control. We also 
recommend including a different cell line as negative target cell control to confirm the preferential 





▲CRITICAL We have successfully used the cell lines listed below in combination with our approach. 
See the Experimental Design section for guidelines on how to adapt and optimize the approach to 
different cell lines of interest.  
!CAUTION All cell lines should be regularly controlled to guarantee that they are authentic and free of 
mycoplasma. 
• A549, Human lung epithelial non-small carcinoma cells (ATTC, CCL-185; RRID: 
https://scicrunch.org/resolver/CVCL_0023.). The cell line was authenticated by STR profiling at 
ECACC and tested for potential mycoplasma contamination every 2 weeks.  
• B16-F1 and B16-F10 cell lines (Cell Services Cancer Research-UK; RRID: 
https://scicrunch.org/resolver/CVCL_0158; https://scicrunch.org/resolver/CVCL_0159). The cell 
line was tested for mycoplasma contamination every 2 weeks.  
• hpMSCs (Cellular Engineering Technologies, CET-Coralville, USA; RRID: 
https://web.expasy.org/cellosaurus/CVCL_1D55 ). Cells were subcultured every 5 days to 
maintain them in exponential growth phase. The cell line was tested for mycoplasma 
contamination every 2 weeks.  
 
Reagents 
▲CRITICAL Prepare all solutions with sterile solvents and store them as indicated.   
• Glacial acetic acid, > 99 % (Sigma Aldrich, CAS no. 64-19-7). Store at room temperature (20-
28°C) in a well-ventilated area.  !CAUTION Corrosive, flammable liquid and vapor 
• Acetone for analysis, ACS, ISO (PanReac AppliChem, CAS no. 67-64-1). Store at room 
temperature in a well-ventilated area. !CAUTION Highly flammable liquid and vapor. 
• Air (UN 1002–GAI3X Praxair). 
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• Ammonium persulfate (APS) for molecular biology for electrophoresis, >99.8 %, (Sigma 
Aldrich, CAS no. 7727-54-0). Store at room temperature. !CAUTION Handle it in laboratory 
fume hood. 
• Analtech Uniplates TLC Silica gel GF 250 µm, 20 x 20 cm (Sigma-Aldrich, cat. no. Z265500). 
• Alexa Fluor 488 Phalloidin (ThermoFisher Scientific, cat no. 21833); RRID: 
https://scicrunch.org/resolver/AB_2532155▲CRITICAL Store at -20 ºC.  
• Anti-CD9 antibody [EPR2949] (Abcam, cat no. ab92726; RRID: 
https://scicrunch.org/resolver/AB_10561589). ▲CRITICAL Store at -20 ºC. 
• Anti-CD63 (for western detection) (Invitrogen, cat no. 10628D; RRID: 
https://scicrunch.org/resolver/ AB_2532983). ▲CRITICAL Store at 4 ºC. 
• Anti-CD63 Monoclonal (MEM-259) antibody Alexa Fluor 488 (ThermoFisher Scientific, cat no. 
MA5-18149; RRID: https://scicrunch.org/resolver/ AB_2539523).  ▲CRITICAL Store at 4 ºC. 
• Anti-CD81 (B-11) (Santa Cruz Biotechnology, cat no. sc-166029; RRID: 
https://scicrunch.org/resolver/ AB_2275892).  ▲CRITICAL Store at -20 ºC. 
• Anti-ALIX (3A9) mouse (Cell Signal Technology, cat no. mAb 2171; RRID: 
https://scicrunch.org/resolver/ AB_2299455).  ▲CRITICAL Store at -20 ºC. 
• Antibiotic-antimycotic 100x (Biowest-bw, cat no. L0010-100). ▲CRITICAL Store at -20 ºC.  
• Anti-Rabbit IgG Antibody (H+L), HRP Conjugated (Bioss Antibodies, cat no. bs-0296G; RRID: 
https://scicrunch.org/resolver/ AB_10856484).   ▲CRITICAL Store at 4 ºC. 
• Anti-Mouse IgG, HRP Conjugated (Sigma Aldrich, Cat no. A9917; RRID: 
https://scicrunch.org/resolver/%20AB_258476). ▲CRITICAL Store at 4 ºC. 
• Bovine Serum Albumin (BSA), (Sigma Aldrich, CAS no. 9048-46-8). ▲CRITICAL Store at 4 
ºC. 
• Bromophenol Blue sodium salt, (Sigma Aldrich, CAS no. 34725-61-6). Store at room 
temperature. 
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• Carbon monoxide (UN 1016 Praxair, 47 BOT 10HA, purity 99.997%).!CAUTION acute toxicity 
(inhalation) - Category 3. Extremely flammable gas. 
• Coomassie Brilliant Blue R-250 protein stain powder (Bio-Rad, cat no. 1610400). Store at room 
temperature. Store at room temperature. 
• Developer Kodak Readymatic (VWR, cat no. KODK5023866). ▲CRITICAL Store at 4 ºC. 
• 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU; 6674-22-2, Sigma-Aldrich, cat. no. 33482) 
• Dichloromethane (DCM; 75-09-2, VWR International Ltd., cat. no. 23354.326). Store at room 
temperature in a well-ventilated place).!CAUTION Causes skin irritation. 
• Dimethylformamide (DMF; dry, 68-12-2, VWR International Ltd., cat. no. 43997.K2). Store at 
room temperature in a well-ventilated place).!CAUTION Acute dermal and inhalation toxicity. 
• Dimethylsulfoxide (67-68-5, Sigma-Aldrich, cat. no. D2650). Store at room temperature. 
• Dimethyl sulfoxide (DMSO) Cell culture grade (PanReac AppliChem, CAS no. 67-68-5). Store at 
room temperature. 
• Distilled, deionized water (ddH2O). 
• DMEM High Glucose w/ Stable glutamine w/ sodium pyruvate (Biowest-bw, cat no. L0103-500). 
▲CRITICAL Store at 4 ºC.  
• DraQ5 (Labclinics, cat no. 65-0880-96). ▲CRITICAL Store at 4 ºC. 
• Dulbecco’s phosphate buffered saline (DPBS) w/o calcium w/o magnesium (Biowest-bw, cat no. 
L0616-500). Store at room temperature. 
• Dulbecco’s modified Eagle medium (DMEM; Sigma-Aldrich, cat. no. D6546). Store at room 
temperature. 
• Epithelial lung carcinoma A549 cells (ATTC, CCL-185TM).Cryopreserved 
• Ethanol (PanReac AppliChem, cat no. 131086.1211). Store at room temperature in a well-
ventilated place).!CAUTION Flammable liquid and vapor. Causes severe eye irritation. 
• Exosome-depleted FBS (Gibco, cat. no. A2720803). ▲CRITICAL Store at -20 ºC.  
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• Fetal Bovine Serum (FBS), qualified, E.U.- approved, South America origin (Gibco, REF. 10270-
106). ▲CRITICAL Store at -20 ºC. 
• Fibroblast Growth Factor-basic (FGF-2), Cat No. 100-18C (PeptroTech, USA). 
• Fixer, Kodak Readymatic (VWR, cat no. KODK5023874). ▲CRITICAL Store at 4 ºC. 
• Fluoromount-G (RMS, cat no. 17984-25). Store at room temperature. 
• Glycerol pure, pharma grade (PanReac AppliChem, CAS no. 56-81-5). Store at room 
temperature. 
• Glycine (Bio-Rad, cat no. 1610717). Store at room temperature. 
• H2O Milli-Q water (resistivity value: 18.2 MΩ·cm @ 25 °C) produced in a Milli-Q system from 
Millipore (Bedford, Germany). 
• High purity Acrylamide/Bis Solution (40 %, 37.5:1) (Bio-Rad, cat no. 1610148). ▲CRITICAL 
Store at 4 ºC. 
• Hydrochloric acid (ACS reagent, 37%, Sigma Aldrich, cat no. 7647-01-0). Store at room 
temperature in a well-ventilated area.  !CAUTION Corrosive. 
• Laemmli lysis buffer (Sigma Aldrich, cat no. 38733). ▲CRITICAL Store at -20 ºC.  
• Lysotracker Green DND-26, (Molecular Probes, cat no. L7526).▲CRITICAL Store at -20 ºC. 
• L-glutamine 200 mM (Gibco, cat. no. 25030-081).▲CRITICAL Store at -20 ºC. 
• Luminata Crescendo Western HRP Substrate (Millipore, cat no. WBLUR0100). ▲CRITICAL 
Store at 4 ºC. 
• Magnesium sulphate anhydrous (MgSO4; 7487-88-9, Fisher Scientific, cat. no. 10003812). 
• Merck TLC Silica gel 60 F254 plates (Sigma-Aldrich, cat. no. 105554). 
• Methanol for analysis, ACS, ISO (PanReac AppliChem, CAS no. 67-56-1). Store at room 
temperature in a well-ventilated place).!CAUTION Flammable liquid and vapor. Causes severe 
eye irritation 
• MycoAlert Mycoplasma Detection kit (Lonza, cat no. LT07-318). Store at room temperature. 
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• N, N, N’, N’- Tetramethylethylenediaminde, BioReagent, suitable for electrophoresis 99%. 
(Sigma Aldrich, CAS no. 110-18-9). Store at room temperature. !CAUTION Handle it in 
laboratory fume hood. 
• Nitric acid (Sigma Aldrich, cat no. 7697-37-02). Store at room temperature. 
• Nitrogen gas (7727-37-9, Praxair). 
• Palladium-sensitive off-on sensor Pro-Res. Prepare it by following the procedure described in 
Box 1.29  
• Palladium Standard for AAS (Fluka Analytical, ref:78437). ▲CRITICAL Store at 4 ºC. 
• Paraformaldehyde (PFA), 4% (w/v) in PBS, (Alfa Aesar, CAS no. J61899). ▲CRITICAL Store 
at 4 ºC. 
• Phosphate buffered saline (PBS; Fisher Scientific, cat. no. 10173433).▲CRITICAL Store at -20 
ºC. 
• Pierce BCA Protein Assay Kit (Thermo Scientific, cat no. 23225). 
• Potassium tetrachloropalladate (II) (Sigma Aldrich, CAS no. 10025-98-6). Store at room 
temperature. ▲CRITICAL Besides potassium chloropalladate (II), some other organometallic 
precursors with a high lipophilic character could be used to increase the Pd exosomal retention, 
but after a previous cytotoxicity and solubility studies. 
• Prestained SDS-PAGE Standards (Bio-Rad, cat no. 1610305EDU). 
• Protease Inhibitor Cocktail Tablets, PhosSTOP (Roche, cat no. 04906845001). ▲CRITICAL 
Store at 4 ºC. 
• Propargyl bromide (106-96-7, Sigma-Aldrich, cat. no. 81831). Store at room temperature. 
• Resorufin (635-78-9, Sigma-Aldrich, cat. no. 424455). Store at room temperature. 
• RIPA Buffer (Sigma Aldrich, cat no. R0278). 
• Saponin from Quillaja Bark pure BC. (PanReac AppliChem, CAS no. 8047-15-2). Store at room 
temperature.  
• Skimmed milk powder (Nestle, ref 8410100002330). ▲CRITICAL Store at 4 ºC. 
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• Sodium dodecyl sulfate (SDS) (Bio-Rad, cat no. 1610301). Store at room temperature. 
• Tween 20 (Sigma Aldrich, CAS no. 9005-64-5). Store at room temperature. 
• Trypsin (Biowest-bw, cat no. X0915-100). ▲CRITICAL Store at -20 ºC. 
• Trypsin-EDTA solution (Sigma-Aldrich, cat. no.T4174). ▲CRITICAL Store at -20 ºC. 
• Transparent fingernail polish (any commercial name and brand is suitable here). 
• Tris Base (> 99.8 pure, Bio-Rad, cat no. 1610716). Store at room temperature. 
• Tris Buffered Saline (TBS) 10X (Bio-Rad, cat no. 1706435). Store at room temperature. 
Equipment 
 
• Adjustable-volume pipettes 2 μL, 10 μL, 200 μL, 1000 μL (Gilson). 
• Air gas tank cylinder pressure controller regulator (PRAXAIR model 2K12). 
• Amersham Hyperfilm ECL (GE Healthcare cat no 28-9068-36). 
• Amersham Hypercassette neutral standard 20x40 cm (GE Heathcare, Life Sciences, RPN11647). 
• Beakers, low form. Borosilicate glass 3.3 100 mL (VWR, cat no. VWRI213-1122). 
• Biosafety cabinet Telstar Bio II Advance (Telstar). 
• BioTek Instrument Synergy HT Microplate Reader (Izasa s/n 208853). 
• Centrifuge 5804R (Eppendorf, cat no. 585000320). 
• CO gas tank cylinder pressure controller regulator (PRAXAIR model 2K12). 
• Confocal microscopes (Spectral Confocal Microscope Leica TCA SP2 and ZEISS LSM800 
Confocal Laser Scanning Microscope). 
• Cooling device recirculating system (Büchi, model F-100 / F-105). 
• DLS Brookhaven 90 Plus Particle size analyzer (Brookhaven Instruments Corporation). 
• Eppendorf microcentrifuge tubes low retention (1.5-mL; Thermo Scientific, cat no. 2448). 
• Flangeless Ferrule Tefzel™ ethylene tetrafluoroethylene (ETFE), 1/4-28 Flat-Bottom, for 1/16" 
(Idex Health and Science, Part#P-200X). 
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• Flangeless Fitting Short, PEEK, 1/4-28 Flat-Bottom for 1/16" OD (Idex Health and Science, 
Part#XP-235X). 
• Forma Steri-Cycle CO2 cell growth incubator (Fisher Scientific, cat no. 15311085). 
• Freezer (Liebher profiline). 
• Fridge (Liebher cat no. 7085638-01). 
• 2-Gel Tetra and Blotting Module (Bio-Rad cat no. 1660827EDU). 
• Glass pipettes (Labbox, cat no. PIPN-230-250). 
• Glass plates 1 mm (Bio-Rad cat no. 1653311). 
• Heraeus™ Fresco™ 17 Microcentrifuge. 
• Heraeus HERAcell® CO2 incubator set up at 37 °C and 5% CO2. 
• High-angle annular dark-field scanning transmission electron microscope (HAADF-STEM) 
Tecnai-F30 operated at 300kV with an Energy dispersive x-ray spectroscopy (EDS/EDX) 
detector. 
• High pressure vessel ( Model 4749, 23 mL, Parr Instrument Company) with a Teflon liner and a 
spanner wrench. 
• High pressure polyether ether ketone (PEEK) tubing (Outside diameter 1/16” , inside diameter 
0.02 “, length 5 feet, Idex Health and Science, Part#1532). 
• Immobilon-P Transfer Membrane 0.45 um pore size (Millipore, cat no. IPVH00010). 
• JP Selecta 3001208 Ultrasonic Cleaning Bath (Fisher Scientific, cat no. 12022085). 
• JP Selecta Precisterm Water Batch (Fisher Scientific, cat no.12027874).  
• LAB20ULFNL (20 µL), LAB10ULFNL (10 µL). 
• Laboratory film (Labbox, cat no. PRFL-001-001). 
• Leica Microscope model DM IL LED (4x, 10x, 20x and 40 x; Leica). 
• Magnetic followers 25 x 10 mm (Fisher Scientific, cat. no. 11547772). 
• Magnetic hotplate stirrer (VWR International Ltd, cat no. 442-0603). 
• Magnetic stirrer/hotplate IKA®-C Mag HS7 (Reference number 0003581200). 
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• Measuring cylinder hexagonal base, class A, Glassco (Labbox, cat no. MCHA-1K0-001). 
• Microcentrifuge Micro Star 17R (VWR, cat no. 521-1647). 
• Microcentrifuge (Thermo Scientific, cat. no. 75002410). 
• Microscope Slides (VWE, car no. 631-1533). 
• Microwave Plasma-Atomic Emission Spectrometer 4100 MP-AES (Agilent Technologies). 
• Mini-protean short plates (Bio-Rad cat no. 1653308). 
• Mini trans-Blot filter paper (Bio-Rad cat no. 1703932). 
• Nanosight NS500 (Malvern Panalytical Cat N 98-4730). 
• Neubauer counting chamber. Depth of 0.1 mm (Marienfeld, cat no. 0640110). 
• Nunc cell culture 96-Well plates, Nunclon Delta surface (Thermo Fisher, cat no. 167425). 
• Nunc cell culture 24-Well plates, Nunclon Delta surface (Thermo Fisher, cat no. 142475). 
• PerkinElmer EnVision 2101 multilabel reader (PerkinElmer, cat. no. 2101-0010). 
• Petri Nunc dish (10-cm; Thermo Scientific, cat no. 150350). 
• Pipette package (maximum volume: 1000, 200, 20 and 10 µL; Eppendorf, cat no. 2231000224). 
• Pipette tips (Labclinics, cat no. LAB1000ULFNL (1000 µL), LAB200ULFNL (200 µL). 
• Plastic Tubing cutter (Idex Health and Science, Part#A-327). 
• PowerPac Basic Power Supply (Bio-Rad cat no. 1645050). 
• Professional aluminum foil (Cellofix). 
• Rotavapor (Büchi, model R-200). 
• Round bottom flask, 25 mL (Quickfit, QFH-082-S). 
• Round cover glasses 13 mm (VWR, cat no. MARI0117530). 
• Screw extractor in a machine laboratory 
• Separating funnel (VWR International Ltd., cat. no. 527-1131). 
• Septum stopper (Fisher Scientific, cat. no. CG302401). 
• Serological pipets (volume: 25, 10 and 5 mL; VWR, cat no. 7516-090P (25 mL), 612-5541P (10 
mL), 612-5523P (5 mL)). 
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• Spectral Confocal Microscope Leica TCA SP2. 
• Stirrer hotplate (Fisher Scientific, cat. no. 10414452). 
• Swagelok SS-42XTS4 Ball Valve-3 way. 
• Time Lapse microscope (Leica, AF6000 LX). 
• ThermoMixer C Eppendorf (VWR International Ltd., cat. no. 460-0222). 
• Transmission electron microscope Tecnai-FEI T20 operated at 200 kV. 
• Tube polyclear 36 mL ultracentrifuge (Thermo Scientific, cat no. 75000571). 
• Tweezers (Ideal-tel, cat no. 7LU1.S). 
• U-Slide 8 Well ; Glass Bottom #1.5H (IBIDI, cat no. 80827). 
• Unstirred water bath (JB Nova, Grant Instruments). 
• Ultracentrifuge Sorval tm WX Ultra Series with AH-629 swinging Bucket Rotor (Thermo Fisher, 
cat no. 75000100). 
• Vortex mixer (VWR, cat no. 444-1372). 




• Fiji (https://fiji.sc). 
• GraphPad (https://www.graphpad.com). 
• ZetaPals software (www.brookhaveninstruments.com) 
• DigitalMicrograph® (https://www.gatan.com/) 
Reagent setup 
▲CRITICAL Prepare all solutions with sterile media and store them as indicated.   
• Heat-inactivation of FBS: Incubate the stock FBS bottle during 30 min at 56 ºC. Heat-inactivated 
FBS can be stored at -80°C for up to one year. 
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• Exosome-depleted FBS: Ultracentrifuge the heat inactivated FBS at 100,000 g during 12 h at 4ºC 
Exosome-depleted FBS can be stored at -20 ºC for one months or at -80ºC for one year. 
▲CRITICAL If an ultracentrifuge is not available commercially available exosome-depleted 
FBS can be used. 
• Supplemented DMEM for hPMSCs. Supplement 500 mL of DMEM (High Glucose w/ Stable L-
glutamine w/ sodium pyruvate) with 10% (v/v) heat-inactivated FBS and with 5 μg mL−1 of FGF-2 
growth factor. The media can be stored at 4°C for up to one month. If some bacterial or fungal 
contamination were observed in the cultures, DMEM supplemented with antibiotics and 
antibiotics is recommended. Add 1 % (v/v) penicillin/streptomycin, 1 % (v/v) amphotericin 
(Antibiotic-antimycotic) to the DMEM. ?TROUBLESHOOTING 
• Ultracen media for hpMSCs. Supplement 500 mL of DMEM (High Glucose w/ Stable L-
glutamine w/ sodium pyruvate) with 10% (v/v) heat-inactivated exosome-depleted FBS, and with 
5 μg mL−1 of FGF-2 growth factor. The media can be stored at 4°C for up to one month. 
▲CRITICAL If an ultracentrifuge is not available, instead use 50 mL of commercially available 
exosome-depleted FBS and supplement with 5 mL of L-glutamine. If some bacterial or fungal 
contamination were observed in the cultures, DMEM supplemented with antibiotics and 
antibiotics is recommended. Add 1 % (v/v) penicillin/streptomycin, 1 % (v/v) amphotericin 
(Antibiotic-antimycotic) to the DMEM. ?TROUBLESHOOTING 
• Supplemented DMEM for cancer cells. Supplement 500 mL of DMEM (High Glucose w/ Stable 
L-glutamine w/ sodium pyruvate) with 10% (v/v) heat-inactivated FBS. The media can be stored 
at 4°C for up to one month. If some bacterial or fungal contamination is observed in the cultures, 
DMEM supplemented with antibiotics and antibiotics is recommended. Add 1 % (v/v) 
penicillin/streptomycin, 1 % (v/v) amphotericin (Antibiotic-antimycotic) to the DMEM. 
?TROUBLESHOOTING 
• Ultracen media for cancer cells. Supplement 500 mL of DMEM (High Glucose w/ Stable 
glutamine w/ sodium pyruvate) with 10% (v/v) heat-inactivated exosome-depleted FBS. The 
media can be stored at 4°C for up to one month. ▲CRITICAL If an ultracentrifuge is not 
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available, instead use 50 mL of commercially available exosome-depleted FBS. If some bacterial 
or fungal contamination were observed in the cultures, DMEM supplemented with antibiotics and 
antibiotics is recommended. Add 1 % (v/v) penicillin/streptomycin, 1 % (v/v) amphotericin 
(Antibiotic-antimycotic) to the DMEM. ?TROUBLESHOOTING hpMSCs cell culture. 
hpMSCs are cultured in supplemented DMEM cell culture medium for hpMSCs at 37 ºC 3 % O2 
humidified atmosphere under hypoxic conditions. Cells should be subcultured every 5 days to 
maintain them in exponential growth phase. 
• Human lung epithelial non-small carcinoma cell culture. Human NSCLCs are cultured in 
supplemented DMEM cell culture medium for cancer cells at 37 ºC, 5 % humidified atmosphere 
under normoxic conditions. Cells should be subcultured every 2 days to maintain them in 
exponential growth phase.  
• B16-F1 and B16-F10 cell culture. B16-F1 and B16-F10 cells are cultured in supplemented 
DMEM cell culture medium for cancer cells at 37 ºC 5 % humidified atmosphere under normoxic 
conditions. Cells should be subcultured every 2 days to maintain them in exponential growth 
phase.  
• APS 10 % (wt/v) solution. Dissolve 0.05 g of APS in 500 µL of Milli-Q water. Prepare always 
freshly and store it at room temperature. ▲CRITICAL STEP The APS should be freshly 
prepared. 
• SDS 10 % (wt/v) solution. Dissolve 0.05 g SDS in 500 µL of Milli-Q water. Store at room 
temperature for up to one month. 
• Tris-HCl 1.5M solution pH= 6.8. Add 80 mL of Milli-Q water to 6 g of Tris Base. Adjust the pH 
to 6.8 with 1N HCL and make up the final volume to 100 mL with Milli-Q water. The Tris-HCl 
can be stored at room temperature for up to one year. 
• Tris-HCl 1.5M solution pH= 8.8. Add 80 mL of Milli-Q water to 18.16 g of Tris Base. Adjust 
the pH to 8.8 with 1N HCL and make up the final volume to 100 mL with Milli-Q water. The Tris-
HCl can be stored at room temperature for up to one year. 
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• Native loading buffer: Mix 1 mL Tris-HCl 0.5M pH=6.8 with 2 mL Glycerol, 1 mL 
Bromophenol Blue and 4.9 mL of Milli-Q water. The native loading buffer can be stored at -20 ºC 
for up to one year.  
• Running buffer.  Mix 200 mL of methanol with 800 mL of Milli-Q water, 14.4 g of glycine, 3.03 
g of Tris Base, and 1 g of SDS. The running buffer can be stored at room temperature for up to 2 
weeks. 
• Transfer buffer. Mix 200 mL of ethanol with 800 mL of Milli-Q water 14.4 g of glycine and 3.03 
g of Tris Base. The transfer buffer can be stored at room temperature for up to 2 weeks. 
• TBS 5% (w/v) milk solution. Dissolve 5 g powder milk in 100 mL TBS 1x. The milk solution 
should be prepared fresh each time. 
• Tween-TBS (TTBS) solution.  Mix 90 µL Tween 20 With 180 mL TBS 1x. The TTBS solution 
can be stored at room temperature for up to 4 weeks. 
• Coomassie blue staining solution. Dissolve 0.025 % (w/v) Coomassie Brilliant Blue R-50 with 
45 % (v/v) Methanol and 6 % (v/v) Acetic Acid. The Coomassie blue staining solution can be 
stored at 4ºC for up to one year. 
• De-staining solution.  Mix 10 % (v/v) Methanol and 30 % (v/v) Acetic Acid. The de-staining 
solution can be stored at 4ºC for up to one year. 
• BSA 1 % (w/v) in PBS. Dissolve 1 g of BSA in 100 mL of PBS. The BSA solution should be 
prepared fresh. 
• Saponin 0.1 % (w/v) in PBS + BSA. Dissolve 0.05 g of saponin in 50 mL of BSA 1 % (w/v) in 
PBS. The saponin solution should be prepared fresh. 
• Protease inhibitor in RIPA buffer. Dissolve 1 tablet in 10 mL RIPA buffer. The protease 
inhibitor solution should be prepared fresh. 
• Potassium tetrachloropalladate (II) exosome reagent.  
1. Prepare a potassium tetrachloropalladate (II) 30 mM stock solution by dissolving 10 mg 
of potassium tetrachloropalladate (II) in 1 mL of PBS. This stock solution should be 
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prepared each time. ▲CRITICAL. Do not use a metallic lab spatula when potassium 
tetrachloropalladate (II) powder is weighed to avoid metal leaching. A plastic spatula can 
be made by cutting the tip of a plastic pipette.  
2. Dilute 60 μL of the potassium tetrachloropalladate (II) stock 30mM solution with 970 μL 
of PBS to obtain 1mL of a 1.84 mM solution. The potassium tetrachloropalladate (II) 
solution is prepared fresh. 
• 100 mM resorufin stock solution in DMSO. Dissolve 21.3 mg of resorufin in 1 mL of DMSO. 
The resorufin stock solution can be stored at - 20 ºC for up to 12 months. 
• Resorufin solution in PBS. Dilute 1 μL of 100 mM resorufin in DMSO with 1 mL of PBS. The 
resorufin solution in PBS can be stored at 4ºC for up to 1 week. 
• 100 mM Pro-Res stock solution in DMSO. Dissolve 25.1 mg of Pro-Res in 1 mL of DMSO. The 
Pro-Res stock solution can be stored at - 20 ºC for up to 12 months. 
• Pro-Res solution in PBS. Dilute 1 μL of 100 mM Pro-Res in DMSO with 1 mL of PBS. The Pro-




Cell culture preparation ● Timing 48-120 h 
▲CRITICAL For any other cell line, exosome amounts, and timings should be adapted. For exosome 
isolation from A549 cell culture it is crucial to culture the cells under optimal conditions before the 
exosome purification procedure according to the following steps: 
1. Maintain cell cultures (5 petri dishes P100) under normoxic conditions until they reach 80 % 
of confluence. 
2. Aspirate the cell culture media carefully with a Pasteur pipette and a vacuum pump. 
3. Wash the cells twice with 6 mL of PBS. ▲CRITICAL STEP Do not add the PBS directly to 
the cell monolayer in order to prevent cell detachment from the surface of the petri dish. 
 24
4. Add 6 mL of Ultracen cell media to each petri dish. 
5. Maintain the cell cultures under normoxic conditions for 48 h. ▲CRITICAL STEP When 
using other cell lines, test various incubation times to find optimal conditions for exosome 
production. 
Exosome isolation ● Timing 5 h 30 min 
6. Take the supernatants (total volume = 30 mL) from all the petri dishes and add them in a 50 
mL falcon tube. ▲CRITICAL STEP Be careful not to remove the cells. 
7. Centrifuge the falcon tube at 2,000 g during 20 min at 4 ºC (Fig.2). 
8. Carefully collect the supernatant with a pipette and transfer it to a polyclear 36 mL 
ultracentrifuge tube. Discard the pellet. 
9. Use PBS to fill another ultracentrifuge tube in order to balance the weight and stabilize the 
ultracentrifuge. 
10. Introduce the ultracentrifuge tubes in the adapters and close them with the proper cap. 
!CAUTION Label the cap of each tube with a number to avoid any confusion. 
11. Assemble the tubes in the AH-629 rotor of the centrifuge.  
12. Introduce the rotor in the centrifuge and close the door of the ultracentrifuge.  
13. Press de vacuum button. 
14. Set the centrifuge speed, time and temperature at 10,000 g, 30 min and 4 ºC, respectively, in 
order to eliminate the organelles and the cellular debris (Fig.2). ▲CRITICAL STEP 
Acceleration and deceleration profiles must be set at 9 and 5, respectively. 
15. Carefully collect the supernatant with a pipette and transfer it into a clean ultracentrifuge tube 
and discard the pellet. 
16. Set the centrifuge speed, time and temperature at 100,000 g, 2 h and 4 ºC, respectively (Fig.2). 
▲CRITICAL STEP Acceleration and deceleration profiles must be set at 9 and 5, 
respectively. 
17.  Discard the supernatant with the aid of a pipette. 
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18. Resuspend the exosomal pellet in 33 mL of PBS with a 25 mL pipette and transfer it to a clean 
ultracentrifuge tube. 
19. Centrifuge the sample again at 100,000 g during 2 h at 4 ºC in order to eliminate the serum 
proteins (Fig.2). ▲CRITICAL STEP Acceleration and deceleration profiles must be set at 9 
and 5, respectively. 
20. Discard de supernatant. 
21. Resuspend the pellet in 1 mL of PBS and take the exosome unquantified fraction to store or 
for characterization. ■ Pause point The exosomes can be stored for long periods at -20 ºC for 
3 months or -80ºC up to 2 years, avoiding freeze and thaw cycles. ▲ CRITICAL STEP Store 
exosomes for use in step 117 as a non-toxic control. 
Exosome quantification ● Timing 45 min 
22. Quantify exosome fraction by total protein amount with the BCA kit. Prepare the BSA 
standards and the BC working reagent and follow the microplate procedure as indicated by the 
manufacturer. Example of total protein quantification is discussed in the Anticipated Results 
section in Fig.5 . 
23. Read the absorbance at 562 nm with the microplate reader using the Gen5 software. 
?TROUBLESHOOTING.  
Pd loading into exosomes ● Timing 14h 
24. Take a volume containing 30 µg of exosomes (according to the concentration in µg/mL 
determined by using the BCA kit in Step 23) and resuspend them in 29 mL of PBS. 
25. Add 1 mL of the 1.84 mM potassium tetrachloropalladate (II) PBS solution to the exosomes 
dispersion (total volume 30 mL) to obtain a 0.06 mM solution. 
26. Incubate the exosomes with the potassium tetrachloropalladate (II) solution overnight at room 
temperature (Fig.2). 
27. Pellet the exosomes by ultracentrifugation at 100,000 g during 2 h at 4 ºC (Fig.2). Discard the 
supernatant, containing the non-internalized potassium chloropalladate (II). 
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28. Resuspend the exosomes loaded with the potassium chloropalladate (II) in 1 mL of PBS. 
■PAUSE POINT It would be highly recommended to continue at this stage of the protocol.  
 
Setup of the high-pressure CO reduction system ● Timing 4h 
! CAUTION Carbon monoxide is listed as highly flammable, colorless, odorless, tasteless and is an 
acutely toxic gas because binds to myoglobin and mitochondrial cytochrome oxidase. Carbon monoxide 
easily combines with hemoglobin to form carboxyhemoglobin which can cause hypoxic stress in healthy 
individuals as a result of the reduced oxygen-carrying capacity of the blood. According to OSHA 
(https://www.osha.gov/dts/sltc/methods/inorganic/id209/id209.html), the Permissible Exposure Limit 
(REL) in an 8-hour time-weighted average (TWA) is 35 ppm and the short-term exposure limits (15 min) 
is 100 ppm. It is strongly recommended that operators familiarize themselves with safety measures 
(https://www.cdc.gov/niosh/topics/cocomp/default.html) and use a portable CO detector with threshold 
alarm set at the TWA value. 
29. Use a screw extractor in a machine laboratory to set a male 1/4"-28 Thread Size port in the cap 
of the Teflon-liner in the high-pressure vessel. 
30.  Cut the PEEK tubing with a tubing-cutter. ▲CRITICAL STEP Improper tube handling and 
cutting are the main causes of tube fitting failure. 
31.  Introduce the short flangeless PEEK fitting and the flangeless ferrule in the PEEK tubing. 
32. Plug the tubing in the female 1/4"-28 Thread port and finger tight. ▲CRITICAL STEP 
Ferrule is required to seal the tubing tightly in the port. 
33. Plug the PEEK tubing to a 3-way valve (inlet). ▲CRITICAL STEP The 3-way valve must 
be piped correctly. Identify the inlet, outlet CO/air and outlet exhaust gas. Add a schematic 
diagram to help with the inlet/outlet identification. 
34. Connect the 3-way valve (CO/Air outlet) to the proper gas tank cylinder pressure controller 
regulator. Select the CO cylinder to reduce the Pd cations or Air cylinder to desorb the 
solubilized CO and quench the redox process. 
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35. Connect the 3-way valve (exhaust outlet) to an exhaust pipe which should be connected to the 
exhaust duct. 
36. Properly secure cylinders in a well ventilated and protected area away from heat, flames, and 
the sun. ! CAUTION It is recommended to introduce the set-up in a laboratory fume hood for 
safe handling. Fit the set-up with a CO gas sensor connected to alarms to alert in the event of a 
leak, or exhaust system failure. ▲CRITICAL STEP Support the gas cylinders to the fume 
hood by using chains or belts. 
37. Check the correct function of the set-up and under-tightened tubing fittings. ▲CRITICAL 
STEP. The integrity of the set-up should be examined at the highest pressure using soapy 
water. The soapy water is applied to the connectors with a pipette. The appearance of bubbles 
indicates the locations of leaks. Check first the integrity of the high pressure system with air 
and then with CO to minimize CO release and safety concerns. ! CAUTION Switch the CO 
gas sensor on before opening the CO valve and set a caution sign to limit the exposure. 
■PAUSE POINT The high-pressure system is ready to be used but a gas leak check should be 
performed daily. 
Pd reduction in the high-pressure CO reduction system ● Timing 60 min 
38. Fill a glass beaker (500 mL capacity) with 200 mL of water and warm it up to 30ºC in the 
magnetic stirrer/hotplate. The stirring rate profile needs to be set at 3 (medium speed) in the 
hot water bath (Fig 3). 
39. Introduce the exosomes (the vial with a volume of 1 mL) prepared in step 28 in the Teflon-
liner. ▲CRITICAL STEP The Teflon-liner cap modified in step 29 is inserted in the high 
pressure vessel. The force required to seal the liner is applied by tightening the vessel 
stainless-steel cap with the spanner wrench 
40. Tight the high-pressure connections and introduce the high-pressure vessel into the hot water 
bath. 
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41. Switch the CO gas sensor on, exhaust outlet (3-way valve) is in the exhaust duct and the glass 
sash window is down (Fig 3). ! CAUTION Keep eye contact with these three components of 
the high pressure system to safely operate. 
42. Open the CO gas cylinder valve (turn the valve handwheel anti-clockwise 2 or 3 turns) and set 
the CO gas tank cylinder pressure controller regulator to 6 bar. ! CAUTION The 3-way valve 
must shut off the CO gas outlet while opening the gas exhaust outlet. 
43. Close the CO gas cylinder valve to check if the CO pressure is stable and there is no CO gas 
leaking in the system. If the CO pressure is stable for 5 min, go to step 44. 
?TROUBLESHOOTING. 
44.  Open the CO gas cylinder valve and flush the high pressure vessel with CO. ▲CRITICAL 
STEP The CO gas outlet in the 3-way valve must be opened and closed for 5 cycles to assure 
the proper gas atmosphere inside the high pressure vessel and remove the air initially located 
at the high-pressure system. 
45. Run the CO mediated redox reaction for 40 minutes to reduce Pd2+ cations to Pd nanosheets. 
46. Close the CO gas cylinder. The 3-way valve must shut off the CO gas outlet while opening the 
gas exhaust outlet (Fig 3). 
47.  Disconnect the CO gas outlet at the 3-way valve. Set the CO gas tank cylinder pressure 
controller regulator to 6 bar. 
48.  Connect the Air gas outlet at the 3-way valve and open the air gas cylinder valve (turn the 
valve handwheel anti-clockwise 2 or 3 turns). Set the air gas tank cylinder pressure controller 
regulator to 6 bar. ▲CRITICAL STEP The 3-way valve must shut off the gas exhaust outlet 
while opening the Air gas outlet (Fig 3). 
49. Flush the high pressure vessel with air. CO solubilized in the exosome solution is desorbed by 
a pressure swing scrub with air. The air gas outlet in the 3-way valve must be opened and 
closed for 5 cycles to assure the proper removal of the CO absorbed. ▲CRITICAL STEP 
This step assures to stop the redox process and the safe handling/opening of the high-pressure 
vessel. 
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50. Open the high-pressure vessel and collect the exosome dispersion. ?TROUBLESHOOTING 
■PAUSE POINT The treated Pd-exosome dispersion can be stored a 5 ºC for at least 1 week. 
The Pd exosomes may also be stored in the freezer at – 20 °C for up to 2 months without 
losing their catalytic activity. Exosome disruption happens after several freeze& thaw cycles. 
Ideally, Pd exosomes should be stored in aliquots and defrosted just before use to avoid 
multiple freeze& thaw steps. 
 
Western Blot of exosomes to determine the alteration of membrane proteins ● Timing 3 days 
51. Clean carefully the 1.0 mm Western blot glasses with ethanol in order to eliminate dust. 
52. Assemble the support for the polymerization of the gels. 
53. Prepare the 12 % (wt/v) and the 8 % (wt/v) running gels (depending on the size of the protein 
of interest) for the conventional or the native Western blot, respectively, using the recipes 
indicated in table 1. ▲CRITICAL STEP The APS should be freshly prepared. 
▲CRITICAL STEP For the native Western blot, SDS must not be added. The reagents must 
be added according to the following order: 
- 1.5 M Tris-HCl, pH=8.8 
- Acryl/Bisacrylamide. 
- H2O. 
-  SDS 
- ▲CRITICAL STEP: The addition of APS and TEMED should be done as fast as 
possible. 
Table 1. Preparation of the running and the stacking gels for Western blot. 
 
Running gel 0.37 M Tris, pH=8.8 Stacking gel 1.12 M Tris, pH=6.8 
Crosslinking 12 % (wt/v) 8 % (wt/v) 4 % (wt/v) 
H2O 1.75 mL 2.75 mL 1.606 mL 
1.5 M Tris-HCl, pH=8.8/ 1.25 mL 1.25 mL 625 µL 
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(to prepare the running gel) 
0.5 M Tris-HCl, pH=6.8 (to 
prepare the stacking gel) 
10 % (w/v) SDS 50 µL 50 µL 25 µL 
Acryl/Bisacrylamide 40 % 
(w/v) 
1.5 mL 1 mL 244 µL 
10 % APS (w/v) 25 µL 25 µL 23.5 µL 
TEMED 2.5 µL 2.5 µL 2.5 µL 
Total volume 4.5 mL 4.5 mL 2.5 mL 
 
54. Add the running gel into the space between the glasses assemblage with a Pasteur pipette and 
fill ¾ of the volume. ▲CRITICAL STEP The upper 2 cm should not be filled in order to 
have enough space for the stacking gel. Remove any bubbles as much as possible. 
55. Add isopropanol in the space between the glasses on top of the running gel in order to 
homogenize the top of the running gel and to prevent the gel from drying. 
56. Allow the gel to polymerize for 45 min at room temperature. 
57. Remove the isopropanol, wash with Milli-Q water and remove the water completely with a 
soaking paper or any other tissue paper. 
58. Prepare the stacking gel as indicated in table 1. ▲CRITICAL STEP The APS should be 
freshly prepared. ▲CRITICAL STEP To perform the native Western blot assay, SDS must 
not be added. The reagents must be added according to the following order: 
- 0.5 M Tris-HCl, pH 6.8 
- Acryl/Bisacrylamide. 
- H2O. 
-  SDS 
- ▲CRITICAL STEP: Quickly add the APS and the TEMED. 
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59. Add the stacking gel into the space between the glasses assemblage with a Pasteur pipette and 
fill ¾ of the volume. ▲CRITICAL STEP Avoid the formation of bubbles and remove them 
as much as possible. 
60. Introduce the Western blot comb and allow the gel to polymerize for 45 min at room 
temperature. 
61. Cover the gel with a humidified paper with Milli-Q water and with aluminum foil. 
■PAUSE POINT The gel can be used directly or kept at 4 ºC for the next day. 
62. Take 30 µg of the Pd-exosome dispersion from Step 50 (according to the concentration in 
µg/mL determined using the BCA kit in Step 23) and add 80 µL of RIPA buffer with protease 
inhibitors. 
63. Keep the sample on ice for 15 min. 
64. Centrifuge the sample at 17,000 g during 10 min at 4 ºC. 
65. Transfer the supernatant where the exosomal proteins are contained to a clean tube and discard 
the pellet.  
66. Add cold acetone to the exosomal fraction at 1:1 (v:v) ratio. 
67. Keep it at -20 ºC for 2 h in order to precipitate the exosomal proteins.  
68. Centrifuge the sample at 17,000 g during 10 min at 4 ºC. 
69. Carefully remove the acetone with a micropipette and allow the sample to dry. 
70. Resuspend the pellet (containing the exosomal proteins) in 10 µL of PBS. 
71. Add 10 µL of room temperature Laemmly buffer to the sample. ▲CRITICAL STEP For the 
native Western blot, mix the sample with the native loading buffer (1:2, v:v sample: native 
loading buffer) and directly proceed to Step 74 (without boiling or denaturing the sample).  
72. Boil the samples in the sample buffer at 90 ºC during 10 minutes.  
73. Immediately, incubate it at 4 ºC during 5 min. ■PAUSE POINT Samples might be kept at -20 
ºC for any other day. 
74. Prepare the running buffer 1x according to the Reagent Setup. 
75. Add the running buffer in the space between the two gels. 
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76. Short spin the sample in the microcentrifuge. 
77. Directly load the sample in the acrylamide gel along with the molecular weight markers (2 
uL).  
78. Take out the Western blot comb, wash the wells and assembly them in the Western blot 
running tank. 
79. Connect the chamber to the electrophoresis power source and run the gel at 100 V for 2h. 
80. To verify if the protein separation has been performed properly, incubate the separating gel 
with the Coomassie blue staining solution overnight. 
81. Remove the Coomassie blue staining solution and de-stain the gel in the de-staining solution 
for 20 min. If the separation of the proteins has not been carried out properly, go to step 51 
and prepare the new gels and samples. Consider adjusting the crosslinking of the gels as well 
as the electrophoresis time in order to optimize the separation of the target protein. 
?TROUBLESHOOTING. 
82. Prepare the transfer buffer 1x according to the Reagent Setup. ▲CRITICAL STEP Transfer 
buffer must be prepared always fresh. 
83.  Measure the gel dimensions, cut a nitrocellulose membrane and two filter papers of the same 
dimensions. 
84. Assemble the transfer folders sandwich, the blot membrane, the filter paper and place the gel 
in the chamber. Make sure no bubbles are trapped into the sandwich.  ▲CRITICAL STEP 
The blot membrane should be on the cathode side and the gel on the anode side. 
▲CRITICAL STEP Maintain always the blot membrane, the filter paper, the gels and the 
transfer folders humidified with the transfer buffer. ▲CRITICAL STEP If needed, activate 
previously the blot membrane with methanol. ?TROUBLESHOOTING 
85. Place the transfer cassette in the wet tank transfer system. 
86. Add the transfer buffer. 
87.  Place an ice block in the tank. 
88. Add a magnetic stirrer in the chamber and put it under stirring at 200 rpm. 
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89. Connect the chamber to the electrophoresis power supply and transfer the proteins at 350 mA 
constant voltage for 4h. ▲CRITICAL STEP For the native western blot, the transference 
should be performed at 300 mV during 12 h at 4 ºC. 
90. Disassemble the transfer cassette and take the nitrocellulose membrane. 
91. Block the nitrocellulose membrane with 5 % (w/v) TBS powder milk overnight at 4 ºC. 
▲CRITICAL STEP If the blot is not properly blocked, unspecific interactions with the 
antibodies could occur. If the blot has been blocked for less time, high background on the blot 
could be observed after its development ?TROUBLESHOOTING. 
92. Wash the membrane with TTBS during 10 min. If the washing steps are not performed 
properly, unspecific interactions and impurities could be observed in the western blot. 
?TROUBLESHOOTING. 
93. Repeat step 92 three times. 
94. Add the primary antibody for 1.5 h at the concentration shown in the table below. 
▲CRITICAL STEP The antibody dilutions should be made according to the manufacturer’s 
recommended ratio. The antibodies may be incubated with the blot for 1-3 h at 4 ºC or room 
temperature depending on the antibody quality and performance, also following the 
manufacturer’s instructions. Some examples of the antibodies that can be employed to 
characterize the exosomes by Western blot are shown in the table below.  
 

























































95. Wash and block the membrane with TTBS during 15 min. ▲CRITICAL STEP If the 
washing steps are not performed properly, unspecific interactions and impurities could be 
observed in the western blot. ?TROUBLESHOOTING. 
96. Repeat step 95 three times. 
97. Add the secondary antibody and incubate for 1 h and 30 min. 
98. Wash the membrane with TTBS during 20 min. 
99. Repeat step 98 three times. ▲CRITICAL STEP The minimum washing time is 1 h. If the 
washing steps are not performed properly, unspecific interactions and impurities could be 
observed in the western blot. ?TROUBLESHOOTING 
100. Add the chemiluminescent substrate to the blot (HRP Luminata Crescendo reagent) following 
the manufacturer´s instructions. 
101. Introduce the blot membrane into the hypercassette. 
102. Reveal the membrane in a room with red light with the developer and fixer. Example Western 
blots are shown in Anticipated Results section (Fig.10) .  ?TROUBLESHOOTING.  
 
Quantification of Pd content in exosomes● Timing 4h 
▲CRITICAL Quantification of the Pd content in exosomes is key before carrying out the in vitro 
catalytic study in Steps 103-108. 
103. Pipette 100 uL of the Pd loaded exosomes dispersion from Step 50 into a clean tube. 
104. Add 150 µL of aqua regia prepared by adding 1/3 (v/v) of HNO3 and 2/3 (v/v) of HCl. 
 35
105. Keep the sample for chemical digestion during 1h at room temperature. 
106. Add 1750 uL of distilled water (final concentration of Aqua regia 10 % (v/v)). 
107. Prepare the Pd standard solutions at different concentration levels (0 ppm, 0,125 ppm, 0,250 
ppm, 0,5 ppm, 1 ppm, 3 ppm, 5 ppm and 10 ppm) with 10 % of aqua regia. 
108. Calibrate the Microwave Plasma-Atomic Emission Spectrometer (MP-AES) equipment with 
the Pd standard solutions and proceed with the analysis of the samples following manufacturer 
instructions. If the Pd loading within the exosomes were very low and below the detection 
limit of the MP-AES an ICP-OES could be used instead but generally high yield is obtained. 
 
Stability analysis of the exosomes ● Timing 10 min/sample 
▲CRITICAL It is important to determine that the exosome stability was not affected along the 
purification process. In this section, exosome integrity is analyzed by evaluation of the particle size as 
well as their zeta-potential. 
109. Size analysis (Steps 109-110): As the number of particles at this stage is unknown, usually from 
the Pd loaded exosome fraction from Step 50 make a dilution 1μl in 1ml or 0.5 ml of PBS 
(1:500) and they might be further diluted to 1:1000 or 1:2000 depending on the sample 
concentration, adjusting to the equipment requirements. Usually, concentration of  exosomes 
range between 106-109particles/mL. 
110. Use a Nanosight to determine the exosome size and perform concentration quantification 
following the manufacturer instructions. Exosomes should have a particle size between 80-
150nm, depending on the cell source of origin. 
?TROUBLESHOOTING     
111. Zeta potential analysis (Steps 111-112): Take the Pd loaded exosome sample from Step 110 
and introduce it in the DLS apparatus.  
112. Connect properly the electrode and measure their surface charge at different time-points, 
following the manufacturer instructions. Exosomes carry a net negative surface charge under 
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physiological conditions due to the glycosylated proteins intercalated within the lipid bilayer 
and the inter- and intramolecular H-bonding, and ion adsorption from the electrolytes present 
in solution. 
 
Cytotoxicity evaluation ● Timing 34 h 
▲CRITICAL It is important to have at least one confluent P100 plate of the cells of interest to test, 
for the evaluation of the toxicity and the internalization of the exosomes into cells. 
113. Remove the cell culture media from a 100% confluent P100 plate and detach the cells with 3 
mL trypsin-EDTA solution, neutralizing them with 3 volumes (9ml) of PBS or cell culture 
medium. Count the cells with a Neubauer chamber. 
114. Prepare a cell suspension in DMEM at 1500 cells/100 µL. 
115. Add 1500 cells (100 µL) to each well in a 96-well plate. 
116. Place the 96-well plate in the cell incubator for 24 h. 
117. Add 0.2, 0.4 and 0.6 µg of Pd loaded exosomes (from Step 50) per 100 µL. ▲CRITICAL 
STEP It is important to have wells of untreated cells (control cells) to be used as 100 % 
viability and cells incubated with unmodified exosomes to be used as controls. ▲ CRITICAL 
STEP Use untreated exosomes from Step 21 as a non-toxic control. 
118. Incubate the cells for 6 h. 
119. Remove the media containing the non-internalized exosomes from the wells. 
120. Wash twice the cells with 100 uL PBS buffer. 
121. Add Cell-Blue reagent following the manufacturer´s instructions. 
122. Read the fluorescence in the plate reader following the manufacturer’s instructions. 
?TROUBLESHOOTING … 
Preparation of the cells for the confocal microscopy analysis ● Timing 27-50 h 
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123. Remove the cell culture media from a totally confluent P100 plate and detach the cells with 3 
mL trypsin-EDTA solution, neutralizing them with 3 volumes (9mL) of PBS or cell culture 
medium. Count the cells with a Neubauer chamber. 
124. Seed the cells at a cell density of 15,000 cells onto 20 mm cover slips deposited onto a 24-well 
plate. 
125. Incubate the cells for 24 h under standard culture conditions.  
126. Add 1 µg (according to the concentration in µg/mL determined using the BCA kit in Step 23) 
of Pd-loaded exosomes from Step 50 to each well diluted in 500 μL Ultracen media. 
127. Incubate the exosomes for 1, 2, 4, 6 and 24 h under standard culture conditions.  
128. Optional: In order to label the lysosomal compartments, add lysotracker to the cells following 
the manufacturer´s instructions  (75 nM of lysotracker for 1h).  
129. Remove media containing the non-internalized exosomes with a Pasteur pipette and a vacuum 
pump. 
130. Wash the cover slips three times with PBS buffer. 
131. Fix the cells with 500 μL 4 % (w/v) PFA during 30 min at room temperature. 
132. Add 500 µL of PBS to the fixed cells. ■ PAUSE POINT The cells can be stored for 24 or 48 
h in the fridge before running the immunocytochemistry. In the case of lysosome labelled 
cells, pass directly to step 142 for nuclei staining. 
Immunochemistry of cells for confocal imaging ● Timing 1h 30 min  
▲CRITICAL Before the permeabilization and the staining of the cells, a humidified chamber must be 
prepared with a Tupperware covered with filter paper and parafilm (Fig. 4a). 
133. Dilute the phalloidin 1/200 in 0.1 % (w/v) Saponin in PBS + BSA solution. Prepare the required 
volume considering 50 µL of the solution for each sample. .▲CRITICAL STEP In addition to 
the visualization of the exosomes loaded with Pd inside the cytosol by labelling the cell nuclei 
and their actin filaments, also the endosomal and the lysosomal pathways should be labelled in 
order to confirm that the exosomes loaded with the Pd are not localized in the lysosomal 
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compartments. In order to label the endosomal pathway, add 0.16 µL of the CD63-Alexa-488 
antibody to 50 µL of 1 % (w/v) Saponin in PBS + BSA for each coverslip. 
134. Deposit one droplet of 50 µL phalloidin or CD63-Alexa-488 solution for each coverslip on the 
parafilm placed inside the humidified chamber (Fig. 4b).  
135. Carefully take the coverslips from the 24 well plate with the tweezers and wash the coverslips 
from Step 131 by introducing them three times with the tweezers in a beaker containing 100 mL 
of PBA + BSA 1 % (w/v).  
136. Permeabilize the cells deposited onto the coverslip by introducing it three times with the 
tweezers in a beaker containing 100  mL of 0.1 % (w/v) Saponin in PBS + BSA. 
137. Deposit the coverslips into the droplets from Step 133. ▲CRITICAL STEP The cell 
monolayer must be in contact with the droplet containing the fluorescent label (Fig. 4c). 
138. Incubate the coverslips for 1 h in the dark and at room temperature. 
139. Take a microscope slide. 
140. Deposit 5 µL of Fluoromount-G with DraQ5 for each coverslip on the slide (Fig. 4d). 
141. Carefully take the coverslips with the tweezers, place them back in a 24 well plate and wash 
them by introducing them with the tweezers in a beaker with 100 mL of PBS + 1% (w/v) BSA  
142. Wash the coverslips by introducing them with the tweezers in a beaker with 100 mL of Milli-Q 
water. ▲CRITICAL STEP Last washing step must be done with Milli-Q water in order to 
eliminate the salts from the PBS.  
143. Deposit the coverslips onto the DraQ5 droplets from Step 139 .▲CRITICAL STEP The cell 
monolayer must be in contact with the droplet (Fig. 4e). 
144. Dry the coverslips overnight in the dark.  
145. Fix the coverslips onto the slips by placing transparent fingernail polish at the edges. ■ PAUSE 
POINT Fixed coverslips can be stored at -20 ºC in the dark for up to 12 months. 
Confocal imaging ● Timing 2- 4 h 
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▲CRITICAL In order to know the optimal incubation time to perform the catalytic experiments inside 
the cells, the internalization of the exosomes loaded with the Pd nanosheets are evaluated by confocal 
microscopy in this section. 
146. Image the coverslips from Step 145 by confocal microscopy with a ×63 oil immersed N.A. 1.40 
objective. Use the reflection of the incident light at Ex/Em of 488/490 nm to directly determine 
the location of Pd-ExosomeA549. Create Z-stack orthogonal projections to enable the 
visualization of the exosomes inside cells cytosol. The table below summarizes the excitation 
and emission wavelengths used for all the antibodies or molecular probes employed in this 







Anti-CD63 Endosomal pathway 490 525 
Lysotracker Lysosomes 504 511 
Phalloidin Actin filaments 495 518 
DraQ5 Nuclei 647 670 
Palladium NPs Pd exosomes Reflection Reflection 
 
▲CRITICAL STEP Before carrying out the experiments, it is crucial to check the absence of signal or 
background coming from other channels to set the acquisition settings. Moreover, it is recommended to 
work in sequential mode to guarantee the absence of channel overlapping. By working in sequential 
mode, the confocal microscope will take all the images from the Z-stack channel and channel separately, 
rather than simultaneously. By checking the absence of overlapping between channels and working in 
sequential mode, we guarantee that all the signal emitted in each channel came from this specific 
excitation wavelength and not from the overlap with other channels.  
?TROUBLESHOOTING.  
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Electron microscopy imaging ● Timing 12 h 
▲CRITICAL This section describes how to perform Cryo-TEM or HAADF-STEM imaging to study the 
morphology of Pd loaded exosomes A549 as well as the location of the produced Pd nanosheets at high CO 
pressure conditions. 
147. Prepare a thin film vitrified specimen using the Pd loaded exosomes form Step 50 with a 
Vitrobot (FEI) in melting ethane. ▲CRITICAL STEP Electron microscopy grid preparation of 
cryogenically immobilized Pd-Exosomes A549 samples requires an extremely rapid sample 
freezing to achieve a vitreous state.  
148. Maintain the sample holder with the specimen grid under cryogenic conditions with liquid 
nitrogen. 
149.  Carry out Cryo-TEM and Cryo HAADF-STEM imaging47-49 using a T20-FEI and F30-FEI 
microscope, respectively. Perform Energy dispersive X-ray spectroscopy (EDS/EDX) analysis 
to determine the presence of Pd nanosheets inside the exosomes. Example data are discussed in 
the Anticipated Results section.  ?TROUBLESHOOTING. 
 
In vitro catalytic study ● Timing 24 h 
▲CRITICAL This section discusses the in vitro conversion of non-fluorescent Pro-Res into highly 
fluorescent resorufin by Pd exosomes in PBS (pH=7.2-7.4, isotonicity). This is an essential step to verify 
the catalytic properties of the exosomes before moving to cellular assays. 
 
150. Add 0.5, 1 and 2 µg of Pd loaded exosomes from Step 50 to a 500 µL solution of Pro-Res in 
PBS (100 μM) in a microcentrifuge tube (1.5 mL).  
151. Sonicate the exosomal suspension for 30 s to avoid agglomeration. 
152. Use a 500 µL solution of 100 μM resorufin in PBS and a 500 µL solution of 100 μM Pro-Res in 
PBS as controls. ▲ CRITICAL STEP Measurements have to be done at least in triplicate. 
153. Shake the reactions in a Thermomixer (0.821 g) for 16 h at 37 °C. 
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154. Sediment the exosomes by centrifugation (17,000 g, 5 min at room temperature) and collect the 
supernatant. 
▲ CRITICAL STEP Carefully collect the supernatant without removing the pellet of 
exosomes. 
155. Measure the solution fluorescence intensity (corresponding to resorufin) on a PerkinElmer 
EnVision 2101 multilabel reader (Ex/Em: 540 /590 nm) and calculate the percentage of 
conversion by comparing the fluorescence intensity of resorufin in PBS (100 μM, equivalent to 
full conversion). Example data are discussed in the Anticipated Results section. 
▲ CRITICAL STEP Resorufin fluorescence maximum excitation/emission is 550nm/585nm. 
?TROUBLESHOOTING. 
 
Time lapse imaging ● Timing 25 h 
▲ CRITICAL This section discusses how to perform time lapse imaging in order to illustrate the fast 
conversion rate of the prodrug to the drug in the presence of the exosomes loaded with the Pd. 
156. Add 1 µg of Pd loaded exosomes from Step 50 to 20 µM solution of Pro-Res in PBS (0.2 mL) 
in a u-slice 8 well Ibidi plate.  
157. Incubate them for 24 h while visualizing under the time lapse microscope. Take frames every 15 
min for 24 h in differential interference contrast (DIC) mode and under red fluorescence 
emission (Ex/em 560/630 nm) with a 20x objective.  
158. Create videos using ImageJ software. Example data are discussed in the Anticipated Results 
section (Fig.12). ?TROUBLESHOOTING. 
 
Intracellular catalytic study ● Timing 48 h 
▲ CRITICAL Before entering more complex functional assays, an intracellular catalytic study is 
essential to validate the capacity of the exosomes to penetrate cells and remain catalytically active inside 
them. 
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159. Starting with 80% confluent T75 flask for adherent cells of A549 cells, remove the 15 mL 
media and detach the cells with 1 mL trypsin-EDTA solution and dilute them in complete 
DMEM media (9 mL). 
160. Seed the cells (100 µL per well containing 1,500 cells) in each well of a 96-well plate and 
incubate them at 37 °C and 5% CO2 for 24 h. 
161. Remove media from the wells and add 100 µL of a freshly-prepared suspension of Pd loaded 
exosomes (from Step 50) in Ultracen media  (0.5 µg of exosomes per 100 µL of media) to each 
well and incubate at 37 °C and 5% CO2 for 6 h. 
162. ▲ CRITICAL STEP Before cell treatment, it is important to sonicate the exosomes suspension 
for 30 s to avoid agglomeration. Remove media from the wells and carefully wash the cells 
twice with 100 µL of PBS buffer per well.  
163. Remove the PBS and add 50 µL of trypsin-EDTA solution to each well in order to detach the 
cells. Deactivate the trypsin by adding 50 µL of 10% (v/v) FBS in PBS buffer.  
164. Collect the cells in microcentrifuge tubes (1.5 mL) and centrifuge at 17,000 g for 5 min at room 
temperature.  
165. Remove the supernatant and suspend the cells in 100 µL of a 100 µM solution of Pro-Res in 
PBS.  
▲ CRITICAL STEP Carefully collect the supernatants without removing the pellet of cells. 
166. Shake the mixture at 0,821 g and 37 °C in a Thermomixer for 16 h.  
167. Analyze fluorescence intensity in a PerkinElmer EnVision 2101 multilabel reader (Ex/Em: 540 






Troubleshooting guide can be found in Table 2. 
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Table 2 | Troubleshooting table. 








solubility of the 
reagents. 
Warm up the stock solutions to 37 ºC before use or 









Use media supplemented with antibiotics and 
antimitotic: 1 % (v/v) penicillin/streptomycin, 1 % 
(v/v) amphotericin (Antibiotic-antimycotic) as 
described in the Reagent setup section in order to 
incubate the cells and during the performance of the 
experiment. 
5 The exosome 
yield is not 
high enough 
to achieve the 
targeted 
amount 
Some cell lines 






If the number of exosomes were lower than expected, 
it would be recommended the scale up of the starting 
plates or the concentration of the exosomes with one 
of the many commercially available column-based 
exosome purification kits. 
43 CO pressure 
is not stable 
in the high 
pressure 
vessel when 
the CO gas 
cylinder is 
closed. 
There is a CO gas 
leak in the high 
pressure system. 
Revise the correct function of the set-up and potential 
under-tightened tubing fittings. Apply soapy water to 
the connectors with a pipette. The appearance of 




This could be 




Use an ultrasound bath to disperse the exosomes 
(sonication time = 1 min) 





Sample is not 
properly 
denatured, the 
crosslinking of the 
gels is not 
properly adjusted 
to the size of the 
protein of interest, 
or the pH of the 
gels is not suitable 
Go to step 51 and prepare new gels and a new sample. 
Alternatively, adjust the crosslinking of the gels as 
well as the electrophoresis time in order to optimize 





needs to be 
incubated with 
methanol. 
Introduce the membrane blot in methanol during 1 
minute before assembling the transfer sandwich. 
86 Gas bubbles 
are trapped in 
the transfer 
sandwich.  
Glass and filter 




Roll a pipette tip several times over the sandwich to 
push the air bubbles out. 
91 Unspecific 
bands are 
The membrane is 
not properly 
Blocked the blot again as described in Step 91 and 
proceed with antibody incubation and detection as 
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observed in 
the blot.  






the blot as 
black spots or 
non-specific 
bands of the 
target 
proteins.  
The membrane is 
not properly 
washed. 
Increase the washing steps and the washing time. 
102 If the results 
on the WB 
were not as 
expected. 
Western-blotting 






Many issues could happen on the different steps along 
the days. The mostly common problems found and 
how to resolve them could be found on the 
manufacturer´s web page (https://www.bio-
rad.com/en-us/applications-
technologies/troubleshooting-western-blots-with-
western-blot-doctor?ID=MIW4HR15) or in some 
publications (doi: 10.4103/1947-2714.100998) 
110 Size 
distribution 




could not be 
appropriated. 
Modify the sample concentration to optimize the 







degradation of Pd 
If the unmodified exosome control shows also 
toxicity, discard culture media and prepare a fresh one 
to repeat the experiment.  
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Exo  If the unmodified exosome control does not show 
toxicity, analyze whether the structural integrity of the 
Pd Exo has been altered and prepare them again if 
required.   
146 Confocal 
imaging 
results are not 
the expected 
Fluorescence 
microscopy is a 
complex 
technique and 
many steps are 
required to take 




This technique requires proficiency. Troubleshooting 
guides for many of the common errors are provided 












exosomes in the 
area of electron 
microscopy 
analysis is low or 
water ice crystals 
are localized in 
the TEM grid 
 A proper Cryo-TEM specimen preparation minimize 
the presence of water ice crystals, which could have 
similar dimensions than exosomes. However the 
geometry of those crystals is different from the one of 
exosomes. 
 If the density of exosomes in the area of analysis 
were low, it is recommended to analyze different 
areas since the drop casting to prepare the specimen 
could not be homogenous. 
155 Fluorescence 
results are not 
as expected 
Pd-Exosomes 
could be damaged 
or reagent 
If positive control yield the targeted fluoresce 
intensity and the Pd loaded exosomes do not show 




batch of Pd-exosomes to avoid a feasible structural 




results are not 
as expected 
Pd-Exosomes 




If positive control yield the targeted fluoresce 
intensity and the Pd loaded exosomes do not show 
any catalytic activity it is recommended to use a new 
batch of Pd-exosomes to avoid a feasible structural 




results are not 
as expected 
Fluorescence 
signal is not 
detected 
Increase the incubation time of Pd-loaded exosomes 
(step 161). If fluoresce issues still continue, it is 
recommended to use a new batch of Pd-exosomes to 
avoid a feasible structural damage of exosomes 
during their preservation or manipulation. 
 
Box 1: Synthesis of Pro-Res. Timing 24 h. 
Reagents 
! CAUTION Reagents and organic solvents might be toxic and/or corrosive. Use appropriate personal 
protection equipment. 
• 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU; 6674-22-2, Sigma Aldrich, cat. no. 33482) 
• Dichloromethane (DCM-CH2Cl2; 75-09-2, VWR International Ltd., cat. no. 23354.326) 
• Dimethylformamide (DMF; dry, 68-12-2, VWR International Ltd., cat. no. 43997.K2) 
• Magnesium sulphate anhydrous (MgSO4, 7487-88-9, Fisher Scientific, cat. no. 10003812) 
• Methanol (MeOH; 67-56-1, VWR International Ltd., cat. no. 20847.307) 
• Propargyl bromide (106-96-7, Sigma-Aldrich, cat. no. 81831) 
• Resorufin (635-78-9, Sigma-Aldrich, cat. no. 424455) 
Consumables 
 48
• Whatman® filter paper (Sigma Aldrich, cat. no. WHA2200150) 
• Merck TLC Silica gel 60 F254 plates (Sigma Aldrich, cat. no. 1055540001)  
• Analtech 01013 Preparative Uniplates, 20x20cm/Silica G/1000mm Thick/15um (Sigma Aldrich, 
cat. no. Z265500) 
 
Equipment 
• Round-bottom flask 25 mL with septum stopper and magnetic stirring bar 
• Magnetic plate stirrer 
• Büchi® Rotavapor® RII evaporator 
• Büchner funnel 90 mm 
• Büchner flask 500 mL 
• TLC viewing cabinet 
• Aldrich® TLC developing tank 
• Rectangular TLC developing tank for preparative chromatography 
 
Procedure 
1. Dissolve Resorufin (300 mg, 1.4 mmol) in dry DMF (5 mL) in a 25-mL round-bottom flask 
sealed with a septum stopper under N2 atmosphere. 
2. Add 1,8-diazabicyclo[5.4.0]undec-7-ene (390 µL, 2.8 mmol). ! CAUTION 1,8-
diazabicyclo[5.4.0]undec-7-ene is toxic and corrosive. Use appropriate personal protection 
equipment. 
3. Prepare a solution of propargyl bromide (240 µL, 2.8 mmol) in dry DMF (0.5 mL). ! 
CAUTION Propargyl bromide is highly flammable, toxic and corrosive. Use appropriate 
personal protection equipment. 
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▲CRITICAL STEP Water can react with propargyl bromide under basic conditions and 
consume the reagent. It is then critical to carry out the reaction under anhydrous conditions to 
improve the yield. 
4. Add propargyl bromide solution (740 µL) to the reaction mixture and stir at room temperature 
for 18 h. ▲CRITICAL STEP Reaction needs to be monitored by thin-layer chromatography 
(TLC). Take a small aliquot of the reaction mixture and add methanol to dilute it. The final 
compound has a clearly different colour (yellow) than resorufin (pink) in the TLC (eluent 
mixture 5% (v/v) MeOH in CH2Cl2). Rf = 0.35 (Pro-Res); Rf = 0.01 (Resorufin). 
5. Remove the solvent using a rotary evaporator and add DCM to get a sticky precipitated solid. 
6. Filter the mixture to remove the sticky solid and wash the filtrate with H2O (2 x 10 mL) in a 
separating funnel. 
7. Dry the organic fraction (DCM) using MgSO4 and remove the solvent using a rotary 
evaporator. 
The crude can be purified via semipreparative TLC chromatography (2.5% (v/v) MeOH in 
CH2Cl2) to yield the final compound as an orange solid. (75 mg, 21% yield). The final 
compound can be stored at 4°C for up to 12 months.  
PAUSE POINT 
End of Box 1 
 
Timing 
Steps 1-5 Cell culture preparation: 48-120 h 
Steps 6-21 Exosome isolation: 5 h 30 min 
Steps 22-23 Exosome quantification: 45 min 
Steps 24-28 Pd loading into exosomes: 14h 
Steps 29-37 Setup of the high-pressure CO reduction system: 4h 
Steps 38-50 Pd reduction in the high-pressure CO reduction system: 60 min 
Steps 51-102 Western Blot of exosomes to determine the alteration of membrane proteins: 3 days  
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Step 103-108 Quantification of Pd content in exosomes:4h 
Steps 109-112 Stability analysis of the exosomes:10 min/sample 
Steps 113-122 Cytotoxicity evaluation: 34 h 
Steps 123-132 Preparation the cells for confocal microscopy: 27-50 h 
Steps 133-145 Immunochemistry of cells for confocal imaging: 1h 30 min 
Step 146 Confocal imaging: 2- 4 h 
Steps 147-149 Electron microscopy imaging: 12 h 
Steps 150-155 In vitro catalytic study: 24 h 
Steps 156-158 Time Lapse Imaging: 25 h 
Steps 159-167 Intracellular catalytic study: 48 h 





Before attempting the synthesis of Pd nanosheets within exosomes it is crucial to have a high enough 
amount of exosomes from the cells cultures. Figure 5 depicts the normalized amount of exosomes (μg of 
exosomes quantified as total protein content obtained by BCA assay) produced by a million of A549, 
B16-F1, B16-F10 and hpMSCs when they were cultured in vitro.  
Pd loading into exosomes  
It is important to determine if Pd nanosheets are properly loaded into exosomes. Considering the 
dimensions of exosomes (100-140 nm) and Pd nanosheets (thickness= 1.4 nm) we use cryo-electron 
microscopy to verify the native morphology of the exosomes and to determine the Pd nanosheet 
distribution within exosomes. Cryo-Transmission Electron Microscopy (Cryo TEM) and Cryo High-
Angle Annular Dark field-Scanning Transmission Electron Microscopy (Cryo HAADF-STEM) are well 
suited to confirm that Pd nanosheets are grown inside exosomes and that the morphology of the exosomes 
does not suffer alterations (Fig. 6 a). CO has dual role in the formation of Pd nanosheets: 1) it functions as 
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a reducing agent and 2) it serves as a selective capping agent. CO has a preferential adsorption to basal 
{111} planes of Pd nanocrystals, favoring an anisotropic growth with a sheet shape. The anisotropic 
growth of Pd nanosheets inside exosomes can be observed in the HAADF-STEM inset image depicted in 
Fig. 5a. and in Fig. 6 b. Due to the ultrathin geometry of this nanosheets (1.4 nm), they are clearly 
observed (high contrast) when they are perpendicularly oriented to the TEM grid. Energy Dispersive X-
ray Spectroscopy (EDS) analysis can be used to confirm the chemical load of exosomes since PBS salts 
can also crystallize in the TEM grids and other artefacts could arise from the TEM sample preparation, 
exhibiting high contrast. Then, the presence of artefacts can draw wrong conclusions and a chemical 
analysis  is key to discard them (Fig. 6c). Fig. 7 depicts representative TEM images of Pd nanoengineered 
exosomes derived from mouse melanoma cell lines with two aggressive states, low metastatic B16-F1 and 
high metastatic B16F10 and human placenta-derived mesenchymal stem cells (hPMSCs). In all cases it 
can be observed that Pd nanosheets were successfully assembled inside the exosomes. 
 
Once the presence of Pd nanosheets into exosomes is confirmed, it is crucial to determine the 
biocompatibility and the optimal time-point of cellular uptake of the Pd loaded exosomes. The 
performance of cell viability assays at different concentrations of Pd loaded exosomes is required to 
determine the optimal concentration range to perform cell-based studies (Fig. 8). On the other hand, the 
efficiency of the catalytic reaction depends on the localization of the Pd loaded exosomes in the different 
compartments of the cell (in the first steps of the endosomal pathway or even, in the lysosomal 
compartments). Confocal microscopy of the Pd nanosheets in combination with immunocytochemistry of 
actin/nuclei and markers of the endosomal pathway/lysosomal compartments will allow to establish the 
incubation time required for Pd loaded exosomes and cells to fulfill the following requirements: 1) have 
the maximum amount of Pd loaded exosomes inside the cells to have a maximum efficient bioorthogonal 
reaction and 2) Having the Pd loaded exosomes in the endosomal pathway rather than in the lysosomal 
compartments. Orthogonal projections of Fig 9 and Supplementary Video_1 demonstrate the presence of 
the Pd loaded exosomes inside the cell cytoplasm. Moreover, purple pixels of Fig. 10a indicated with a 
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yellow arrow evidences the localization of the Pd loaded exosomes in the endosomal pathway rather than 
in the lysosomal compartments after 6 h of incubation (Fig. 10b). 
Exosomes characterization- Size and functionality 
Fig. 11a shows NTA results of control exosomes and Pd-loaded exosomes derived from A549 cells. Both 
types of exosomes revealed a typical exosome diameter of approximately 100 nm. In order to obtain high 
quality NTA exosomal measurement, the parameters obtained by the equipment have to be optimized 
according to manufacturer´s indications.  
Western blot analysis of Pd-loaded exosomes indicates the expression of CD81 and ALIX proteins as 
shown in Fig. 11b. CD81 is a protein from the tetraspanin family of around 26 kDa. ALIX is another 
typical exosomal protein of approximately 96 kDa. Both proteins are involved on endocytosis and on the 
exosome/ multivesicular body biogenesis pathways.  
Finally, Fig. 11c includes a phase analysis light scattering of Pd loaded exosomes. When the electrode is 
connected with the sample, a voltage is applied to the cell and the movement of the particles under the 
influence of the applied electric field is registered by the instrument providing a phase change in light 
scattered produced by particles moving under the influence of an applied electric field. This phase change 
is directly proportional to the electrophoretic mobility of the exosomes and thus, to their zeta potential.   
 
Pd exosomes as catalytic devices 
As observed in Fig. 12a, treatment of Pd exosomes with Pro-Res under physiologically-relevant 
conditions (37 °C, pH 7.4, isotonicity) results in a dramatic increase of the fluorescence emission of the 
solution. After 16 h of incubation, the 100 µM Pro-Res solution containing Pd exosomes at concentrations 
of 0.2 µg per 100 µL (or higher) reaches fluorescence intensity values near or equal to those of a 100 µM 
resorufin solution, indicating full conversion efficacy. These results confirm the catalytic properties of the 
exosome-catalyst hybrids. The ex vitro catalytic properties of the Pd exosomes were also evaluated by 
time-lapse microscopy. Fig. 13 includes three sequences recorded during 24 h of different conditions 
(using Pro-Res as negative control, Res as positive control and finally Pro-Res incubated with the 
catalytic exosomes). This figure corroborates the activation of the Pro-Res mediated by the catalytic 
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exosomes and the subsequent appearance of the fluorescence. On the contrary, when Pro-Res was 
incubated in absence of the Pd exosomes, no fluorescence was observed, even when the reaction time was 
augmented. 
To test their capacity to catalyze bioorthogonal reactions inside cells, we treated A549 cells with Pd 
loaded exosomes for 6 h and. After elimination of non-internalized exosomes, cells were incubated with 
Pro-Res and we monitored the fluorescence intensity of the medium. After 24 h, the fluorescence 
intensity reached approx. 21% of the value of a 100 µM resorufin solution, confirming the capacity of the 
intracellular Pd devices to convert Pro-Res into resorufin (Fig. 12b). While the obtained value is lower to 
that found in vitro, it is important to note that only a fraction of the Pd exosomes incubated with A549 
cells are effectively internalized. This conversion value it would be more than sufficient to generate 
bioactive levels of a pharmacological agent from inactivated prodrugs or probes. In the field of 
bioorthogonal prodrug activation, most prodrug strategies aim to achieve over 100-fold difference in 
activity between the prodrug (inactive) and drug (active). Considering the hypothetical situation in which 
a prodrug is inactive at 100 µM and the parented drug displays high anticancer activity at 10 µM, a 20 % 
conversion of 100 µM of the inactive prodrug would generate 20 µM of the anticancer drug, leading to a 
very potent antitumor effect. Once the intracellular catalytic properties of the Pd exosomes are confirmed, 
they are ready to be used for more complex studies.     
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Figure legends 
Fig 1| A schematic description of the production of Pd-exosomes for targeted bioorthogonal catalysis. 
Fig 2| A schematic of the exosome isolation and Pd2+ loading. (a) schematic overview of the exosome 
isolation procedure. (b) Schematic overview of the Pd-Exosome production. Exos = exosomes. 
Fig 3| A schematic of the high-pressure CO reduction system and summary of the 3-way valve positions 
to produce Pd-exosomes  
Fig 4| Preparation and Fixation of cells on coverslips for inmuno-labeling of cells.(a) Preparation of the 
humidified chamber with the parafilm and the humidified filter paper. (b) 50 µL droplet containing the 
phalloidin. (c) Coverslip deposited onto the phalloidin droplet and incubated during 1 h for actin staining. 
(d) Deposition of 5 µL of Fluoromount-G with DraQ5 on the slip. (e) Incubation of the coverslips with 
the DraQ5 for nuclei staining.  
Fig. 5| Total protein exosomes quantification by BCA assay for A549, B16-F1, B16-F10 and hpMSCs. 
 
Fig 6| Electron microscopy analysis of Pd loaded exosomes (a)- Cryo High-Angle Annular Dark field-
Scanning Transmission Electron Microscopy (Cryo HAADF-STEM) images of Pd loaded exosomes. 
Inset, a high magnification Cryo HAADF-STEM image to show the Pd nanosheet thickness. Scale bar = 
50 nm. Scale bar inset= 5 nm. S1 and S2 areas marked in dashed red line are the locations where the 
chemical analysis (EDX) was performed for elemental identification; (b) High magnification Cryo-TEM 
image of Pd nanosheets loaded within the exosome. Scale bar= 5 nm. Scheme of the Pd nanoheets with 
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different 3-D orientation to understand the features depicted in the TEM Image-(c)- Energy dispersive X-
ray spectra from areas S1 and S2 marked in dashed red line in (a) corroborating the presence of Pd. 
Fig 7| Representative TEM images of Pd nanoengineered exosomes. Different images are derived from: 
Tumor cells (B16-F1 and B16-F10) and Human placenta-derived mesenchymal stem cells 
(hPMSCs).Scale bar=20 nm 
 
Fig 8| Cell viability assays (A549 cells) at different concentrations of Pd loaded exosomes. 
 
Fig 9|. Confocal images of A549 cells incubated with Pd-loaded exosomes during 24 hours. Green 
channel corresponds to actin filaments labelled with phalloidin, blue channel shows the nuclei stained 
with draQ5 and red channel shows the Pd-loaded exosomes visualized directly by reflection.  Scale bar 50 
μm. Scale bar zoom 12.5 μm. Orthogonal projections derived from confocal images of A549 cells reveal 
red sports of exosomes agglomerates inside cell cytoplasm. Scale bar 50 μm. Scale bar zoom 5 μm  
 
Fig 10.| Confocal microscopy images of cells incubated with Pd loaded exosomes. (a)- The endosomal 
route is labelled with CD63 (blue) and the Pd loaded exosomes are directly observed by reflection (red). 
Purple pixels (indicated with a yellow arrow) evidence the localization of the Pd loaded exosomes in the 
endosomal pathway. (b)- Lysosomes are labelled with lysotracker (blue) and Pd loaded exosomes are 
directly observed by reflection (red). The majority of the Pd loaded exosomes are not colocalizing with 
the lysosomal compartment. Scale bars 5 µm. Scale bar zoom images 0.5 μm 
 
Fig. 11| Exosome characterization. (a) NTA measurements of exosomes size and concentration of empty 
(right) and Pd loaded (left) vesicles. (b) Western Blot of CD81 and ALIX proteins expressed in A549 
derived exosomes. (c) Phase change analysis obtained during zeta potential measurements of Pd loaded 
exosomes.  
Fig 12|. Pd-mediated conversion of non-fluorescent Pro-Res to fluorescent resorufin. (a), In vitro catalytic 
study in PBS at 37 °C. Fluorescent analyses (λex/em = 540/590 nm) were performed after 16 h incubation 
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of Pro-Res (100 μM) with Pd exosomes (0.1, 0.2 and 0.4 μg per 100 μL). Fluorescence intensity of Pro-
Res in the absence of Pd exosomes (100 μM, green) and Resorufin (100 μM, purple) were used as 
negative and positive controls, respectively. Error bars= ± 1 SD (n = 3); ANOVA, *** P< 0.001. (b), 
Intracellular catalytic study. Fluorescent analysis (λex/em = 540/590 nm) was performed after 24 h 
incubation of Pro-Res (100 μM) with A549 cells pre-treated with Pd exosomes (0.2 and 0.5 μg per 100 
μL). Fluorescence intensity of untreated A549 cells directly incubated with Pro-Res (100 μM, green) and 
Resorufin (100 μM, purple) were used as negative and positive controls, respectively. Error bars= ±1 SD 
(n = 3); ANOVA, * P< 0.05, *** P< 0.001.  
Fig. 12| Time lapse frame sequence during 24 h of Pro-Res (negative control), Res (positive control) and 
Pro-Res with the catalytic Pd-exosomes. The appearance a clear red fluorescent signal (compared with the 
Res) when the Pro-Res was incubated with the Pd-exosomes was clearly visible. The samples were 




- Supplementary Video 1: Confocal Z-stack sequence of A549 cells incubated with Pd-ExosA549. 
Actin is labelled with phalloidin (green), nuclei are stained with Draq5 (blue) and the Pd-Exos 
were directly visualized by reflection (red) 













